Oseltamivir (GS 4104) is an orally administered inhibitor of neuraminidase (NA), targeting influenza viruses. It effectively inhibits various strains including influenza A/H3N2, A/H1N2, A/H1N1, and B viruses, with mean IC50 values of 0.67, 0.9, 1.34, and 13 nM, respectively[1].
体内研究
Oseltamivir (20 mg/kg/day, pO., twice daily for 10 days) demonstrated efficacy in preventing mortality associated with H1N1pdm virus infection in mice[2].
Oseltamivir, administered orally at a dosage of 10 mg/kg/day for 5 days, in combination with either 15 mg/kg or 30 mg/kg of Amantadine, demonstrates increased efficacy in protecting against H5N1 influenza virus infection in mice compared to monotherapy[3].
Oseltamivir is also employed in combination with Ribavirin, Favipiravir, or Peramivir to prevent influenza virus infection in mice[4][5].
Oseltamivir/奥司他韦 细胞实验
Cell Line
Concentration
Treated Time
Description
References
P3 FVB mouse cochlear explants
450 nM (EC50)
24 hours
Oseltamivir phosphate protected mouse cochlear explants from cisplatin-induced outer hair cell death
Clin Transl Med. 2024 Aug;14(8):e1803.
P3 FVB mouse cochlear explants
505 nM (EC50)
24 hours
Oseltamivir carboxylate protected mouse cochlear explants from cisplatin-induced outer hair cell death
Clin Transl Med. 2024 Aug;14(8):e1803.
Oseltamivir/奥司他韦 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Cisplatin-induced hearing loss model
Oral
50 mg/kg
45 minutes before administration, continued for 3 days
Oseltamivir significantly reduced cisplatin-induced hearing loss and outer hair cell death
搜索
